BioTech January 1, 2019

Acting for VC investor into BioTech venture, Inoviv

We acted for a new seed-stage UK VC fund on its investment into Inoviv, a BioTech company developing bespoke biomarker tests to identify patients and demonstrate treatment efficacy for novel therapies.

Inoviv claims its tests: “support pharmaceutical companies in running successful clinical trials and in maximising access to marketed therapies”.

Deal/project: Seed investment

Date closed: January 2019

Space: BioTech

Other lawyers and advisors: Cooley acted for the company



Team advising
Share on Social Media